AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca is currently conducting a Phase 1, open-label clinical trial titled ‘A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).’ The study aims to investigate the effect of AZD2389 on FAP occupancy in the liver of participants with advanced liver fibrosis, a significant step in understanding potential treatments for this condition.
The trial is testing the drug AZD2389, administered orally, alongside a diagnostic PET scan using the radioligand [68Ga]Ga-FAPI-46. The purpose is to assess the drug’s impact on liver fibrosis, potentially offering a new therapeutic avenue.
This interventional study uses a non-randomized, sequential model without masking, focusing on treatment as its primary purpose. The study design allows for adaptive changes, ensuring flexibility in response to interim results.
The trial began on May 26, 2025, with the latest update submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
The outcome of this study could significantly influence AstraZeneca’s stock performance, as positive results may enhance investor confidence and market position. This is particularly relevant in the competitive pharmaceutical landscape, where advancements in liver fibrosis treatment are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.